Combined dendritic cell and anti-TIGIT immunotherapy potentiates adaptive NK cells against HIV-1

树突状细胞和抗TIGIT免疫疗法联合应用可增强适应性NK细胞对抗HIV-1的能力。

阅读:6
作者:Ildefonso Sánchez-Cerrillo ,María Agudo-Lera ,Olga Popova ,Ilya Tsukalov ,Marta Calvet-Mirabent ,Ignacio de Los Santos ,Lucio García-Fraile ,Patricia Fuentes ,Cristina Delgado-Arévalo ,Juan Alcain ,Nerea Sánchez-Gaona ,Judith Grau-Expósito ,María Lázaro-Díez ,Cecilia Muñoz-Calleja ,Arantzazu Alfranca ,Meritxell Genescà ,Julia G Prado ,Vladimir Vrbanac ,Alejandro Balazs ,María José Buzón ,María L Toribio ,María A Muñoz-Fernández ,Francisco Sánchez-Madrid ,Enrique Martín-Gayo

Abstract

Natural Killer (NK) cells are promising candidates for targeting persistently infected CD4 + T cells in people with HIV-1 (PWH). However, chronicity of HIV-1 infection impairs NK cell functionality, requiring additional strategies to potentiate their cytotoxic activity. This study demonstrates that dendritic cells primed with nanoparticles containing Poly I:C (Nano-PIC-MDDC) enhance the natural cytotoxic function of NK cells from effective responder PWH. These NK cells exhibit increased proportions of NKG2C+ cell subsets capable of eliminating HIV-1 infected CD4 + T cells through the TRAIL receptor. In contrast, in non-responder PWH, elevated expression of the inhibitory receptor TIGIT is associated with reduced frequencies of NKG2C + NK cells and diminished TRAIL expression. TIGIT blockade restores cytotoxicity of NK cells from non-responder PWH against HIV-1-infected cells by upregulating TRAIL. Furthermore, combining Nano-PIC-MDDC-primed NK cells with anti-TIGIT immunotherapy in humanized NSG mice reduces the expansion of HIV-1 infected cells, preserves NKG2C + NK cell precursors and increases TRAIL expression in tissue. Collectively, these findings support the combined use of Nano-PIC-MDDC and TIGIT blockade as a promising immunotherapeutic strategy toward an HIV-1 cure.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。